Clinical Research Directory
Browse clinical research sites, groups, and studies.
Back to Studies
ACTIVE NOT RECRUITING
NCT06049134
PHASE4
Immunogenicity and Clinical Efficacy of 20-valent Pneumococcal Conjugate Vaccine (PCV20) in Lymphoma Survivors After Treatment With Anti-CD20 Therapy
Sponsor: M.D. Anderson Cancer Center
View on ClinicalTrials.gov
Summary
To compare the effects of a pneumococcal vaccine called PCV20 when given as a single dose versus a boosted regimen to patients who previously received anti-CD20 therapy as treatment for B cell lymphoma.
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
30
Start Date
2023-10-06
Completion Date
2027-12-01
Last Updated
2026-03-09
Healthy Volunteers
No
Conditions
Interventions
BIOLOGICAL
PCV20
Given by Injection into the muscle
Locations (1)
M D Anderson Cancer Center
Houston, Texas, United States